MedDataX Logo

Study to Evaluate Multiple Doses of ERB-041 in Healthy, Female Japanese Subjects

NCT ID: NCT00434187

Last Updated: 2009-07-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-08-31

Study Completion Date

2006-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective is evaluate the safety, tolerability, and pharmacokinetics of multiple doses of ERB-041, an investigational drug, in healthy, female Japanese subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Assess the Safety and Tolerability of E6742 in Japanese Healthy Adult Participants

NCT04683185

Healthy Volunteers
COMPLETED PHASE1

Study Evaluating the Safety and Pharmacokinetics (PK) of Ascending Single IV Doses of ERB-257 in Healthy Japanese Males

NCT00722202

Healthy Subjects
COMPLETED PHASE1

A Study to Test the Safety and Tolerability and Pharmacokinetics of Single Doses of UCB0107 in Healthy Japanese Subjects

NCT03605082

Healthy Japanese Volunteers
COMPLETED PHASE1

Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants

NCT04444050

Healthy Participants
COMPLETED PHASE1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of AEB071

NCT00409929

Healthy
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ERB-041

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy as determined by the investigator on the basis of medical history and screening evaluations.
Minimum Eligible Age

20 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

Wyeth is now a wholly owned subsidiary of Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kan-nondai, Tsukuba-shi, Ibaraki, Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3142A2-115

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB0942 in Healthy Japanese and Caucasian Subjects
NCT03168984 COMPLETED PHASE1
Study to Evaluate the Safety, Local and Systemic Tolerability, and Pharmacokinetics of Multiple-Dose Topical Administration of PF-07038124 in Japanese Healthy Participants
NCT04863417 COMPLETED PHASE1
Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants
NCT05431634 COMPLETED PHASE1
Evaluate The Safety, Tolerability and Pharmacokinetics Of Multiple Ascending Oral Doses Of WCK 4873 In Healthy Adult Volunteers
NCT03979859 COMPLETED PHASE1
A Study of RO6799477 in Healthy Volunteers
NCT01893437 COMPLETED PHASE1
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-99677 in Healthy Adult Japanese Participants.
NCT04958291 COMPLETED PHASE1
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64264681 in Healthy Male and Female Participants
NCT03607513 COMPLETED PHASE1
Study Evaluating the Safety and Pharmacokinetics of Ascending Single IV Doses of ERB-257
NCT00722501 COMPLETED PHASE1
A Single and Multiple Ascending Dose Study of BMS-986318 in Healthy Participants
NCT04082741 WITHDRAWN PHASE1
Multiple Oral Doses Of PH-797804 In Healthy Japanese Adult Subjects
NCT01217918 COMPLETED PHASE1
Study Evaluating IMA-638 in Healthy Japanese
NCT00340327 COMPLETED PHASE1
A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are Tolerated
NCT05183347 COMPLETED PHASE1
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Oral WCK 2349
NCT04874324 COMPLETED PHASE1
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ 53718678 in Healthy Japanese Adult Participants
NCT02398591 COMPLETED PHASE1
Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects
NCT03980080 COMPLETED PHASE1
Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants
NCT04079101 COMPLETED PHASE1
A Single and Multiple Dose Study of PF-05221304 in Healthy Japanese Adults
NCT03597217 COMPLETED PHASE1
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants
NCT05813717 COMPLETED PHASE1
A Study in Healthy Japanese Men to Test How Different Doses of BI 690517 Are Taken Up in the Body and How Well They Are Tolerated
NCT03608072 COMPLETED PHASE1
A Study to Assess the Safety and Tolerability of Single and Multiple Ascending Doses of Oral RO7020531 in Chinese Healthy Participants.
NCT03530917 COMPLETED PHASE1
Single and Multiple Ascending Doses of AZD1981 in Japan
NCT00698282 COMPLETED PHASE1
Safety of AEB071 in Healthy Volunteers and to Compare the Ethnicity, Metabolic, and Safety Effects Between Caucasian and Japanese Healthy Subjects
NCT00416546 COMPLETED PHASE1
Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants
NCT07039929 TERMINATED PHASE1
A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects
NCT05653037 ACTIVE_NOT_RECRUITING PHASE1
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707
NCT05068466 COMPLETED PHASE1